| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.027 | 0.9 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | JQ-1:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.9 |